

Capstone Therapeutics Corp.

Form SC 13G

March 24, 2016

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. __)*

Capstone Therapeutics Corp.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

14068E109

(CUSIP Number)

March 22, 2016

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

o Rule 13d-1(d)

Page 1 of 5

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11	19.4% ¹
	TYPE OF REPORTING PERSON
12	IN-OO**

** See Item 4.

¹ The percentage reported in this Schedule 13G is based upon 40,885,411 shares of Common Stock outstanding according to the Form 10-Q filed by the Issuer on November 9, 2015.

Page 3 of 5

Item 1(a). Name of Issuer: Capstone Therapeutics Corp.

Item 1(b). Address of Issuers' Principal Executive Offices: 1275 West Washington Street
Suite 104
Tempe, Arizona 85281

Item 2(a). Name of Person Filing: Lloyd I. Miller, III

Item 2(b). Address of Principal Business Office or, if None, Residence: 3300 South Dixie Highway
Suite 1-365
West Palm Beach, Florida 33405

Item 2(c). Citizenship: U.S.A.

Item 2(d). Title of Class of Securities: Common Stock

Item 2(e). CUSIP Number: 14068E109

Item 3. IF THIS STATEMENT IS FILED
PURSUANT TO RULE 13d-1(b) OR
13d-2(b) or (c), CHECK WHETHER
THE PERSON FILING IS A:

Not Applicable, this statement is filed
pursuant to 13d-1(c)

Item 4. OWNERSHIP: Mr. Miller has sole
voting and dispositive power with respect
to 7,836,045 of the reported securities as
(i) manager of a limited liability company
that is the adviser to certain trusts, (ii)
manager of a limited liability company
that is the general partner of a certain
limited partnership, (iii) manager of a
limited liability company, and (iv) an
individual. Mr. Miller has shared voting
and dispositive power with respect to
90,344 of the reported securities as an
advisor to the trustee of a certain trust.

(a) 7,926,389

(b) 19.4%

(c) (i) sole voting power: 7,836,045

(ii) shared voting power: 90,344

(iii) sole dispositive power: 7,836,045

(iv) shared dispositive power: 90,344

Item 5. OWNERSHIP OF FIVE PERCENT OR
LESS OF A CLASS:

Not Applicable

Page 4 of 5

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Other than shares held directly by Lloyd I. Miller, III, persons other than Lloyd I. Miller, III have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the reported securities.

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not Applicable

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

Not Applicable

Item 9. NOTICE OF DISSOLUTION OF GROUP:

Not Applicable

Item 10. CERTIFICATION:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 5 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 24, 2016 /s/ Lloyd I. Miller, III
Lloyd I. Miller, III